# Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

> **NCT00698815** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 130 (actual)

## Conditions studied

- Recurrent Non-Small Cell Lung Carcinoma
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pemetrexed Disodium
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT00698815
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-15
- **Primary completion:** 2011-12-01
- **Final completion:** —
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698815, "Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00698815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*